Are you hesitant about delegation due to perceived time constraints and potential pitfalls?
Ever wondered about the different scenarios of delegation within the Situational Leadership Model?
How do you empower individuals to seamlessly transition from unfamiliarity to unconscious competence in a task?
Have you considered the task-specific nature of experience and the pitfalls of assuming universal skills?

In this episode, I navigate the significance of delegation, a skill indispensable for statisticians, managers, and professionals across diverse fields. Building on a 2018 episode that explored effective delegation principles, I now scrutinize delegation through the lens of the Situational Leadership Model.

Here are the highlights of the episode:

Step into the festive spirit with me in this special Christmas episode, where I warmly wishes you all, my listeners, a joyous holiday season and reflects on the successes of 2023.

As the year comes to a close, I share exciting plans for 2024, offering a sneak peek into the upcoming episodes, webinars, and interactive learning experiences that will empower statisticians to thrive in the new year.

Join me for a delightful blend of reflection, gratitude, and anticipation as I unwrap the gifts of knowledge and growth that The Effective Statistician has in store for you.

Here are the key points I am sharing in this episode:

How do we define estimates effectively?
What challenges arise in estimating treatment policy, particularly in the context of missing data and patient discontinuation?
How can statistical approaches be communicated more transparently to both experts and the broader audience?

In this episode, Oliver Keene and I delve into the realm of estimating treatment effects with continuous outcomes over time. We also delve into the article by Natey Ting, published in 2023, advocating for a reevaluation of estimation techniques. Ting's emphasis on the last observation analysis sparks a robust discussion as we dissect its applicability in the context of treatment policy and its potential limitations.

We also discuss the following key points:

Are you curious about aggregate safety assessment planning?

Whether you’re an experienced statistician or just starting out in the field, your work increasingly demands that you apply principles of aggregate safety assessment planning. With an ever-changing and advancing landscape filled with data and technology advancements, it is essential to stay current on this topic.

In episode, Greg and I explore what aggregate safety assessment planning is, its components, its importance for statistically informed decisions, and how it ties into patient safety initiatives.

You will be equipped with a better understanding of the fundamentals so that your efforts can make powerful contributions in research settings and support meaningful health outcomes for patients everywhere.

Stay tuned while we discuss the following key points:

Are you ready to dive into the future of statistical work in drug development?
Are large language models like ChatGPT the future of data analysis?
How does the increasing trend toward transparency and open-source programming influence the pharmaceutical industry?

In this episode, Benjamin Piske and I explore the dynamic landscape of trends shaping the statistical field. As we reconvene after a significant hiatus, we delve into intriguing topics that will undoubtedly get the interest of anyone involved in statistical analysis for pharmaceuticals.

Join the conversation as we discuss the implications of these trends and more, offering insights that will challenge your perspective on the evolving nature of statistical work.

We talk about these 6 Trends:

Have you ever wondered about the real factors that contribute to success in statistics?

Is it just luck, or is there something more to it?

In this episode, I explore the practical aspects of luck, opportunities, and preparation in the world of statistics.

How can strategic networking, targeted training, and building confidence influence your career trajectory?

Join me as I take a straightforward look at how these elements can impact your professional journey in statistics. Here are the key points:

Ever wondered about the intricate connections between observational studies and the Estimand framework in the pharmaceutical industry?

How do the challenges in multi-country primary data collection unfold, and what crucial role do assumptions play in propensity score methods?

In this captivating episode, I'm excited to have Artemis Koukounari, an accomplished statistician and associate director in real-world evidence at Novartis, join me for an insightful conversation.

Join us as we explore these questions and more, unraveling the complexities of real-world evidence and offering a glimpse into the future of data research in the pharmaceutical realm.

We also discuss the following key points:

In today's episode, I embark on a personal and insightful journey with Mirjam Sandlos, not just a business coach but my personal guide in breaking mental chains.

Mirjam, a seasoned business consultant, shares her expertise in dismantling limiting beliefs or "Glaubenssatz" that shape our realities. These subconscious codes, acquired in our formative years, become barriers to achieving our goals.

Our discussion emphasizes the power of thoughts and the need to change both beliefs and accompanying mental imagery. By altering thought patterns, we raise our vibrational frequency, attracting positivity.

Join us as we delve into these key points:

In this new episode, I and Guillaume Desachy delve into the world of R and its impact on the pharmaceutical industry. Guillaume, a Statistical Science Director at AstraZeneca in Sweden, shares his insights and experiences in fostering an R community within the company.

Embarking on the exploration of Guillaume's journey in building the R at AstraZeneca community beckons a series of intriguing questions:

How does a modest idea transform into a community boasting over 1,600 collaborators within just three years?
What challenges and decisions shape the trajectory of such a community, leading to the retirement of initiatives like AZTidyTuesday?
How does the community navigate the intricate balance between growth and sustaining valuable initiatives?

We also talk about the following key points: